Opinion|Videos|November 25, 2024

Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing

Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.

Video content above is prompted by the following:

  • How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
  • What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME